Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise
Share this:
Published: 5 Jan 2016

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..